Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Crosslink Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, MELCHIOR, JAMES RYLAND. Consequently, MELCHIOR, JAMES RYLAND is the busiest examiner. The prosecution is localized in 1 distinct art unit. This profile reflects a highly focused and singular current patent application for the company.
With only 1 pending office action, the company's current interaction with the patent office is concentrated on one case. MELCHIOR, JAMES RYLAND handles the entirety of the pending workload, which is situated in 1 distinct art unit. This concentration means that the outcome of the company's current prosecution efforts in the Biotechnology & Pharmaceuticals technology area depends entirely on the evaluation of this one examiner. The focus on 1 distinct art unit is consistent with the single pending action being processed by 1 distinct examiner. This targeted approach allows the company to focus its resources on a single pharmaceutical application, though it remains dependent on the specific review of MELCHIOR, JAMES RYLAND.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19195720 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | MELCHIOR, JAMES RYLAND | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19195720 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | MELCHIOR, JAMES RYLAND | 1644 | §112DP | Final Rejection | — | Pending | Apr 30, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCrosslink Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
James Ryland Melchior has the most, with 1 of Crosslink Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
